The addition of topotecan to carboplatin and paclitaxel as first-line therapy for advanced ovarian cancer; is it possible only with peripheral blood stem cell support?

Autor:	N, Cacciari, C, Zamagni, A, Martoni
Rok vydání:	2000
Předmět:	Adult Ovarian Neoplasms Neutropenia Dose-Response Relationship Drug Paclitaxel Antineoplastic Combined Chemotherapy Protocols Hematopoietic Stem Cell Transplantation Humans Female Middle Aged Topotecan Thrombocytopenia Carboplatin
Zdroj:	European journal of gynaecological oncology. 21(1)
ISSN:	0392-2936
Popis:	A phase I study was performed in order to evaluate the tolerability of the combination of fixed doses of carboplatin and paclitaxel and escalated doses of topotecan as first line chemotherapy for advanced epithelial ovarian cancer. Three stage III and one stage IV patients entered the study. The dose limiting toxicity (neutropenia and thrombocytopenia) was reached at the first dose level: paclitaxel 175 mg/m2 on day 1, carboplatin AUC 5 on day I and topotecan 0.5 mg/m2 daily from day 1 to day 3. We conclude that it is not possible to add topotecan to standard regimens of carboplatin and paclitaxel without bone marrow support.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::224003a7a67f1f0cebac557f92d12d6b https://pubmed.ncbi.nlm.nih.gov/10726628 Zobrazit plný text záznamu